US 12,168,783 B2
Oncodialysis system and method for personalized autologous cancer vaccine and blood purification
David Michaeli, Ashkelon (IL); and Menashe Michaeli, Ashkelon (IL)
Filed by David Michaeli, Ashkelon (IL); and Menashe Michaeli, Ashkelon (IL)
Filed on Oct. 17, 2023, as Appl. No. 18/380,909.
Application 18/380,909 is a continuation in part of application No. 18/129,866, filed on Apr. 2, 2023, granted, now 12,042,590.
Prior Publication US 2024/0327798 A1, Oct. 3, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/09 (2010.01); C12M 1/00 (2006.01); C12M 1/26 (2006.01); C12M 1/42 (2006.01); C12N 13/00 (2006.01)
CPC C12N 5/0694 (2013.01) [C12M 33/14 (2013.01); C12M 35/02 (2013.01); C12M 47/10 (2013.01); C12N 13/00 (2013.01)] 28 Claims
OG exemplary drawing
 
1. A method of preparing an autologous vaccine against cancer for a mammalian subject using components of exogenous blood of the subject and without use of a surgical invasive biopsy, the method comprising:
using a conically arranged or conically shaped coil positioned upstream of a blood filtration system, a base of the conically arranged or conically shaped coil situated at a widest portion of the coil, the base configured to receive the exogenous blood of the subject flowing peristaltically;
filtering, by the blood filtration system, exogenous blood plasma of the exogenous blood, the exogenous blood outputted from the conically arranged or conically shaped coil, to remove an oncological component by removing at least one of tumor cells, tumor stem cells and tumor breakdown products in at least one step and then filtering, by centrifuging, the at least one of the tumor cells, tumor stem cells and tumor breakdown products in a further step to remove tumor exosomal peptides and leave a remaining amount of tumor breakdown products, the removed tumor exosomal peptides not configured to be recognized as an antigen by an immune system of the subject; and
converting the removed tumor exosomal peptides into an antigen by directing electromagnetic radiation at the removed oncological component, so as to convert an outer surface of the removed tumor exosomal peptides into a coagulated outer surface so as to be recognizable as the antigen by the immune system; and
using a processing unit to control the filtering of the blood plasma.